J.P. Morgan Upgrades Biogen to Overweight From Neutral
Biogen shares climbed 3.7% to $234.06 after J.P. Morgan analyst Chris Schott upgraded the stock, citing upcoming clinical-trial catalysts.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Biogen shares climbed 3.7% to $234.06 after J.P. Morgan analyst Chris Schott upgraded the stock, citing upcoming clinical-trial catalysts.
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled. Top 5 Upgrades: JPMorgan upgraded American Express (AXP) to Overweight from Neutral with a price target of $400, up from $328. The company trades at a